TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02619370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation card game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Study: NCT03606109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
Study: NCT02752048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-205
Description: 2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 group: Placebo group. Oral administration for 24 weeks, BID after meal
Study: NCT03888898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reusable respirator fit test and competency evaluation
Description: Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control fit test evaluation
Description: control comparator for fit testing time threshold
Study: NCT03112317

Intervention type: OTHER
Intervention: Prevention of hypothermia
Description: Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.

Intervention type: OTHER
Intervention: Prevention of hypothermia
Description: Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
Study: NCT02430077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Obeticholic Acid - placebo drug
Study: NCT05053282

Intervention type: OTHER
Intervention: endurance running exercise
Description: regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session

Intervention type: OTHER
Intervention: endurance running exercise
Description: regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
Study: NCT00274716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02863354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT02291627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coopdech
Description: Video laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: optical laryngoscopy
Study: NCT00132769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873
Description: MK-0873 1.25 mg twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
Study: NCT01866189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET and MRI
Description: F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
Study: NCT03832192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care.coach Avatar (HELP-Protocolized)
Description: care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
Study: NCT04955808

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02420860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04693663

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Relex-Smile surgery
Description: surgery using Relex-Smile
Study: NCT04394416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Therapeutic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT03099382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
Study: NCT00037934

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity robot
Description: Robotic upper extremity neuro-rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Supervised Upper Extremity Exercises
Description: Arm ergometer, reaching, and stretching exercises
Study: NCT01918852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teysuno

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03763409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: active drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02088645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Study: NCT01040299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GangTrainer and tDCS
Description: The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: control group1
Description: The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group2
Description: The control group 2 receive a total of 10 treatments with convectional physiotherapy.
Study: NCT01099878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycling Exercise with Functional Electrical Stimulation
Description: The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cycling exercise
Description: The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
Study: NCT01217723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.

Intervention type: OTHER
Group type: OTHER
Intervention: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
Description: The standard preparative regimen can be myeloablative or reduced intensity.
Study: NCT00512473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: 0.9 % NaCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: 0.5 mg genotropin administered as a bolus at t = 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: 30 mg Somavert administered at t = - 36 hours
Study: NCT03338829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive incentive
Description: Compensation is paid for each glucose test completed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss aversion
Description: Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
Study: NCT00799188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
Study: NCT04352894

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence guided peritoneal exploration
Description: Intravenous injection of ICG
Study: NCT03788941

Intervention type: PROCEDURE
Intervention: left atrial appendage closure and catheter ablation
Description: Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation.
Study: NCT01291524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 400 to 500 calorie
Description: A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 600- 750 calorie
Description: A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, bedtime
Description: A single oral dose of 330 mg controlled release tablet administered at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered in the evening
Study: NCT03630432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT00349219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
Study: NCT03749330

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CICU Team And Loved Ones Communicating (CICU TALC)
Description: When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
Study: NCT02810457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKB238 (bevacizumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin (bevacizumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT04073537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Anlotinib blank analog capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study: NCT01872312

Intervention type: DEVICE
Group type: OTHER
Intervention: treatment with valves (The Spiration® IBV Valve System)
Description: treat BPF
Study: NCT02742662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable technology, smartscale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone applications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Weight Management Visits

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Weight Management Visits
Study: NCT01583140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness control
Description: Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
Study: NCT00652054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
Study: NCT03307252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet
Study: NCT03538314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 (300 microgram)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF (37,5 or 75 microgram)
Study: NCT03307252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet
Study: NCT03099382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
Study: NCT02685163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidant ice-cream
Description: Narutal Antioxidant ice-cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Ice-cream
Description: Natural Control Ice-cream
Study: NCT00499369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT03178474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®
Description: JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOFER Infant formula,TOFER®
Description: TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
Study: NCT03665246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Mothers and Babies Course
Description: The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
Study: NCT00090337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Patients undergo standard care
Study: NCT02617446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV of matching saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
Study: NCT01267968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 1500 mg (dosing detailed in Arm description)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 1500 mg (dosing detailed in Arm description)
Study: NCT02924337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT02650609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01994395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Stride Management Assist (SMA) System
Description: Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.